Evidence map›Paper›PMID 40506738›Full record

ArticleOrphanet journal of rare diseases2025

Household costs in the United States for accommodating functional impairments associated with Duchenne muscular dystrophy: results from a caregiver survey.

Bryan Innis, John Jarvis, Taylor Renteria, Ivana Audhya

Abstract read
In one paragraph

Article in Orphanet journal of rare diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Bryan InnisSarepta Therapeutics, Inc., Cambridge, MA, USA. BInnis@sarepta.com.ORCID http://orcid.org/0009-0008-7274-3942
John JarvisMedicus Economics, Milton, MA, USA.
Taylor RenteriaMedicus Economics, Milton, MA, USA.
Ivana AudhyaSarepta Therapeutics, Inc., Cambridge, MA, USA.

Funding

Sarepta Therapeutics, Inc. Sarepta Therapeutics, Inc.
6 · The paper itself

Abstract

backgroundIndividuals with Duchenne muscular dystrophy (DMD) often require mobility aids and accessible homes and vehicles. Because these accommodations are not typically reimbursed by insurance, costs largely fall upon patients' families. Additionally, families often incur high out-of-pocket costs for DMD-related health services and treatments. Research describing these expenses is important to understand the full financial cost associated with DMD. The objective of this study was to quantify household costs associated with DMD-related accommodations.

methodsA cross-sectional, retrospective online survey was conducted among United States-based family caregivers who provided informal (unpaid) care to ≥ 1 household member with DMD for ≥ 12 months and paid for ≥ 1 home/vehicle-related expense in the past 5 years. Participants reported costs, external financial support, and affordability for (1) home/vehicle purchases/modifications, (2) non-reimbursed medical equipment, (3) non-reimbursed health services or drugs, and (4) other household expenses. Costs were averaged over all respondents and among those incurring costs (conditional means). Average costs were stratified by ambulatory status, upper-limb impairment, insurance coverage type, home ownership status, and annual combined household income.

resultsAmong 90 caregivers, 94.4% were female, 90.0% were White, and 82.1% were the primary caregiver. The mean (standard deviation [SD]) age of individuals with DMD (n = 106) was 14.5 (5.3) years. Over half (59.4%) were reported as non-ambulatory, 23.6% as ambulatory, and 17.0% as transitioning from ambulatory to non-ambulatory. Average (SD) household costs over the past 5 years were $78,303 ($78,411) for home/vehicle expenses and $14,071 ($27,427) for medical equipment. Major home/vehicle expenses included purchasing/modifying a handicap-accessible vehicle (64% in past 5 years; conditional mean 5-year cost: $47,997), modifying home entrances (61%; $16,750), and modifying bathrooms (46%; $13,512). Powered wheelchairs were the leading driver of medical equipment costs (43%; $15,718). Annual recurring, non-reimbursed health service and drug costs were $13,642 (SD $41,792). Other recurring annual household expenses were $2593 (SD $4144). Household costs generally increased with more advanced disease progression. Households were able to pay for some expenses using external funding from the US government (e.g., Medicaid waivers) and non-government resources (e.g., charitable foundations, independently raised funds). However, many caregivers reported having to forgo purchases due to prohibitive costs.

conclusionsHouseholds incur substantial costs to accommodate the functional impairments experienced by individuals with DMD.

Indexed as

CaregiversMuscular Dystrophy, DuchenneAdolescentAdultCost of IllnessCross-Sectional StudiesFemaleHealth ExpendituresHumansMaleMiddle AgedRetrospective StudiesSurveys and QuestionnairesUnited StatesCaregiverDuchenne muscular dystrophyEconomic burdenFamilyImpactIndirect costs

Identifiers

PMID40506738
PMCPMC12160368

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.